BR112013009185A2 - uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável. - Google Patents

uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.

Info

Publication number
BR112013009185A2
BR112013009185A2 BR112013009185A BR112013009185A BR112013009185A2 BR 112013009185 A2 BR112013009185 A2 BR 112013009185A2 BR 112013009185 A BR112013009185 A BR 112013009185A BR 112013009185 A BR112013009185 A BR 112013009185A BR 112013009185 A2 BR112013009185 A2 BR 112013009185A2
Authority
BR
Brazil
Prior art keywords
mexiprostil
treat inflammatory
bowel syndrome
irritable bowel
inflammatory bowel
Prior art date
Application number
BR112013009185A
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro Assandri
Luigi Moro
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of BR112013009185A2 publication Critical patent/BR112013009185A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112013009185A 2010-10-19 2011-10-18 uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável. BR112013009185A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2010A001908A IT1402047B1 (it) 2010-10-19 2010-10-19 Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
PCT/IB2011/054627 WO2012052918A1 (en) 2010-10-19 2011-10-18 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
BR112013009185A2 true BR112013009185A2 (pt) 2016-07-26

Family

ID=43738034

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009185A BR112013009185A2 (pt) 2010-10-19 2011-10-18 uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.

Country Status (9)

Country Link
US (1) US20130202704A1 (enExample)
EP (1) EP2629778B1 (enExample)
JP (1) JP5885749B2 (enExample)
KR (1) KR20140008306A (enExample)
CN (1) CN103167874A (enExample)
BR (1) BR112013009185A2 (enExample)
CA (1) CA2812891A1 (enExample)
IT (1) IT1402047B1 (enExample)
WO (1) WO2012052918A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
CN108685929A (zh) * 2012-04-23 2018-10-23 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
JP6814162B2 (ja) * 2015-05-04 2021-01-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 結腸に治療剤を送達するための組成物及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704825A1 (de) * 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
DE3876230T2 (de) * 1988-01-28 1993-05-06 Merrell Dow Pharma Verfahren und zwischenprodukte.
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US20050159485A1 (en) * 2002-01-04 2005-07-21 Jost-Price Edward R. Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
ES2327251T3 (es) * 2004-07-02 2009-10-27 Allergan, Inc. Analogos de prostaglandina.

Also Published As

Publication number Publication date
CA2812891A1 (en) 2012-04-26
JP5885749B2 (ja) 2016-03-15
JP2013544795A (ja) 2013-12-19
EP2629778A1 (en) 2013-08-28
CN103167874A (zh) 2013-06-19
IT1402047B1 (it) 2013-08-28
WO2012052918A1 (en) 2012-04-26
KR20140008306A (ko) 2014-01-21
US20130202704A1 (en) 2013-08-08
EP2629778B1 (en) 2016-09-21
ITMI20101908A1 (it) 2012-04-20

Similar Documents

Publication Publication Date Title
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
IN2012DN02471A (enExample)
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
MY151104A (en) Novel use
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
BR112013009185A2 (pt) uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
BRPI1008259A2 (pt) composição para prevenção ou tratamento de síndrome do intestino irritável

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]